Crescent Capital Partners
Cressida Mort is an experienced professional with a diverse background in investor relations, development, and marketing. Currently serving as the Director of Investor Relations at Crescent Capital Partners since October 2023, Cressida previously held significant roles at TAS The Armidale School as the Director of Development and Marketing from January 2008 to July 2023, and as a Brand and Communications Consultant at PwC and ASX. Cressida's career began at National Australia Bank-NAB as a Foreign Exchange Dealer and also includes notable positions in marketing and communications at Gilbert + Tobin and ASX. Cressida holds a Master of Business in Administration (Marketing) from the University of Technology Sydney and a Bachelor of Arts from the University of Sydney.
This person is not in any teams
Crescent Capital Partners
Crescent Capital Partners (Crescent) is a Sydney-based private equity firm investing in middle-market companies located in Australia and New Zealand with enterprise values between A$100 million and A$500 million. Crescent was formed in 2000 and has established itself as one of Australasia’s leading middle market private equity firms with its last three funds ranked as top quartile global funds (measured in either USD or AUD), as measured by Cambridge Associates. Crescent’s investment focus is on high-growth companies and sectors, or in industries that are undergoing structural change or that lend themselves to consolidation. Crescent’s role is to accelerate and support the senior management teams of these businesses in reaching their aspirational targets and goals. Crescent has a differentiated investment process that combines thematic and proprietary deal sourcing, with a disciplined and analytical approach to investing and a proactive approach to driving value at portfolio companies. Crescent has particular experience and skills in financial services, healthcare, branded and industrial businesses. In particular, Crescent has been the most active private equity manager in healthcare transactions in Australia measured by number of investments made in the past 10 years. Crescent has had a strong track record in delivering superior returns to investors through successful exits. Crescent is now investing our $1 billion Crescent VII (2023 vintage).